XCRT Quote, Financials, Valuation and Earnings

Humana, Inc. has a net margin of -- compared to Xcelerate, Inc.'s net margin of -2.39%. Xcelerate, Inc.'s return on equity of -- beat Humana, Inc.'s return on equity of 6.77%.

Xcelerate, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Humana, Inc. has an analysts' consensus of $212.17 which suggests that it could grow by 19.31%. Given that Humana, Inc. has higher upside potential than Xcelerate, Inc., analysts believe Humana, Inc. is more attractive than Xcelerate, Inc..

Xcelerate, Inc. has a beta of 0.885, which suggesting that the stock is 11.541% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.439, suggesting its less volatile than the S&P 500 by 56.107%.

Xcelerate, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana, Inc. offers a yield of 1.98% to investors and pays a quarterly dividend of $0.89 per share. Xcelerate, Inc. pays -- of its earnings as a dividend. Humana, Inc. pays out 36% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Xcelerate, Inc. quarterly revenues are $535.4K, which are smaller than Humana, Inc. quarterly revenues of $32.5B. Xcelerate, Inc.'s net income of -$229K is higher than Humana, Inc.'s net income of -$776M. Notably, Xcelerate, Inc.'s price-to-earnings ratio is -- while Humana, Inc.'s PE ratio is 18.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate, Inc. is 1.56x versus 0.17x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Marpai, Inc. has a net margin of -- compared to Xcelerate, Inc.'s net margin of -141.07%. Xcelerate, Inc.'s return on equity of -- beat Marpai, Inc.'s return on equity of --.

Xcelerate, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Marpai, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Xcelerate, Inc. has higher upside potential than Marpai, Inc., analysts believe Xcelerate, Inc. is more attractive than Marpai, Inc..

Xcelerate, Inc. has a beta of 0.885, which suggesting that the stock is 11.541% less volatile than S&P 500. In comparison Marpai, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Xcelerate, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marpai, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xcelerate, Inc. pays -- of its earnings as a dividend. Marpai, Inc. pays out -- of its earnings as a dividend.

Xcelerate, Inc. quarterly revenues are $535.4K, which are smaller than Marpai, Inc. quarterly revenues of $4M. Xcelerate, Inc.'s net income of -$229K is higher than Marpai, Inc.'s net income of -$5.6M. Notably, Xcelerate, Inc.'s price-to-earnings ratio is -- while Marpai, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate, Inc. is 1.56x versus 0.35x for Marpai, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Health Care Organization, Inc. has a net margin of -- compared to Xcelerate, Inc.'s net margin of 14.85%. Xcelerate, Inc.'s return on equity of -- beat Pacific Health Care Organization, Inc.'s return on equity of 11.16%.

Xcelerate, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Pacific Health Care Organization, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Xcelerate, Inc. has higher upside potential than Pacific Health Care Organization, Inc., analysts believe Xcelerate, Inc. is more attractive than Pacific Health Care Organization, Inc..

Xcelerate, Inc. has a beta of 0.885, which suggesting that the stock is 11.541% less volatile than S&P 500. In comparison Pacific Health Care Organization, Inc. has a beta of 0.157, suggesting its less volatile than the S&P 500 by 84.321%.

Xcelerate, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Health Care Organization, Inc. offers a yield of 6.79% to investors and pays a quarterly dividend of $0.10 per share. Xcelerate, Inc. pays -- of its earnings as a dividend. Pacific Health Care Organization, Inc. pays out -- of its earnings as a dividend.

Xcelerate, Inc. quarterly revenues are $535.4K, which are smaller than Pacific Health Care Organization, Inc. quarterly revenues of $1.6M. Xcelerate, Inc.'s net income of -$229K is lower than Pacific Health Care Organization, Inc.'s net income of $235.1K. Notably, Xcelerate, Inc.'s price-to-earnings ratio is -- while Pacific Health Care Organization, Inc.'s PE ratio is 10.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate, Inc. is 1.56x versus 2.19x for Pacific Health Care Organization, Inc.. Usually stocks with elevated PS ratios are considered overvalued.